| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.5 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.037 | 0.5 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |